Affinity Asset Advisors »

Savara shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Savara (SVRA) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Savara

Tip: Access up to 7 years of quarterly data

All positions including Savara held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Savara by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $4.3M 1.2M 3.78

More positions owned by Affinity Asset Advisors

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Apogee Therapeutics (APGE)
Establishment Labs Holdings Ord (ESTA)
Cymabay Therapeutics
Immunovant (IMVT)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Madrigal Pharmaceuticals (MDGL)
Xenon Pharmaceuticals (XENE)
Alkermes SHS Call Option (ALKS)
Kura Oncology (KURA)
Astria Therapeutics (ATXS)
Morphic Hldg (MORF)

View all positions for Affinity Asset Advisors

Top funds holding Savara

NEA Management Company
Jennison Associates
BlackRock
Vanguard Group
Frazier Life Sciences Management
VR Adviser
Vivo Capital
Wellington Management Company
Henderson Group
Millennium Management
Nantahala Capital Management
Superstring Capital Management
Connor, Clark & Lunn Investment Management
Bank of New York Mellon
ClariVest Asset Management

View all funds holding Savara